Search results17–19
| Author (year) | Research design | Location | Study population | Results |
| Jain et al17 (2022) | Retrospective cohort study | India | A total of 167 individuals with m-CNV therapy participated in the study, resulting in the inclusion of 167 eyes. Among these, 59 eyes were treated with intravitreal ranibizumab monotherapy, while 108 eyes received bevacizumab monotherapy. | The only notable factor that predicted recurrence was the number of injections administered to treat the disease in the initial episode (Cox proportional HR 2.89–3.07, 95% CI 1.28–7.45; p=0.005). Following 12 months, eyes that received a single injection during the first episode exhibited a recurrence rate of 12%, while eyes that necessitated three or more injections in the initial episode experienced a recurrence rate of 45%. |
| Cicinelli et al18 (2023) | Retrospective cohort study | Italy | The study included a total of 310 eyes with active myopic macular neovascularisation and the median duration of follow-up was 3.5 years. | Multiple recurrences were predicted by advanced age (HR=1.13 (95% CI 1.04–1.27) for every 10-year increase, p=0.006), larger size of myopic macular neovascularisation (HR=1.06 (95% CI 1.01–1.13) for every 1 mm² increase, p=0.04) and a juxtafoveal location (HR=1.88 (95% CI 1.28–2.77) compared with extrafoveal, p=0.001). |
| Jing et al19 (2022) | Retrospective cohort study | China | A total of 48 patients with pathologic myopia choroidal neovascularization (PM-CNV) who received conbercept treatment and underwent a period of monitoring for at least 6 months were included in the study, comprising 48 eyes in total. | The binary logistic regression analysis demonstrated a significant correlation between PM-CNV recurrence and various factors, including the height of hyper-reflective foci, CNV area, as well as the presence of ellipsoid zone and retinal pigment epithelium abnormalities (p<0.05). |
m-CNV, myopic choroidal neovascularisation; PM-CNV, pathologic myopia choroidal neovascularisation.